These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38871822)

  • 21. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
    Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
    J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
    Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M
    Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
    Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
    J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.
    Straube A; Stude P; Gaul C; Schuh K; Koch M
    J Headache Pain; 2021 Nov; 22(1):133. PubMed ID: 34742252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erenumab for episodic migraine prophylaxis.
    Overeem LH; Neeb L; Reuter U
    Expert Rev Neurother; 2019 Aug; 19(8):751-757. PubMed ID: 30614741
    [No Abstract]   [Full Text] [Related]  

  • 26. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
    Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
    J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erenumab for episodic migraine.
    Datta A; Gupta S; Maryala S; Aggarwal V; Chopra P; Jain S
    Pain Manag; 2022 Jul; 12(5):587-594. PubMed ID: 35313740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of erenumab in Japanese patients with migraine.
    Suzuki K; Suzuki S; Shiina T; Haruyama Y; Kobayashi S; Shioda M; Hirata K
    Heliyon; 2024 Feb; 10(4):e26568. PubMed ID: 38420497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M; Leroux E; Pagé G
    Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine.
    Autio H; Purmonen T; Kurki S; Mocevic E; Korolainen MA; Tuominen S; Lassenius MI; Nissilä M
    Neurol Ther; 2022 Mar; 11(1):223-235. PubMed ID: 34888760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.
    Giamberardino MA; Affaitati G; Costantini R; Cipollone F; Martelletti P
    J Pain Res; 2017; 10():2751-2760. PubMed ID: 29263689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
    Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
    J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
    Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
    Raffaelli B; Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Reuter U
    J Headache Pain; 2022 Mar; 23(1):40. PubMed ID: 35350990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.